ABBVIE INC (4AB.DE) Stock Price, Forecast & Analysis
Europe - FRA:4AB - US00287Y1091 - Common Stock
4AB.DE Key Statistics, Chart & Performance
The current stock price of 4AB.DE is 201 EUR. In the past month the price increased by 2.24%. In the past year, price increased by 27.68%.
4AB.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 71.89 | 47.36B | ||
| ARGX.BR | ARGENX SE | 72.88 | 48.01B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.63B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.33B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.33B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.80B | ||
| 5CV.DE | CUREVAC NV | 5.24 | 1.03B | ||
| NANO.PA | NANOBIOTIX | N/A | 876.56M | ||
| PHIL.MI | PHILOGEN SPA | 20.53 | 684.22M | ||
| IVA.PA | INVENTIVA SA | N/A | 494.46M | ||
| FYB.DE | FORMYCON AG | N/A | 366.65M | ||
| VLA.PA | VALNEVA SE | N/A | 332.16M |
Related stock screener links
About 4AB.DE
Company Profile
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 55,000 full-time employees. The company went IPO on 2013-01-02. The firm is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Its Immunology products include rheumatology, dermatology and gastroenterology. Its Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere, and Epkinly. The Company’s Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Its Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and Other eye care. Its Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its Venclexta is a B-cell lymphoma 2 (BCL-2) inhibitor used to treat blood cancers.
Company Info
ABBVIE INC
1 N Waukegan Rd
North Chicago ILLINOIS US
Employees: 55000
Phone: 18479327900
ABBVIE INC / 4AB.DE FAQ
What does ABBVIE INC do?
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 55,000 full-time employees. The company went IPO on 2013-01-02. The firm is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Its Immunology products include rheumatology, dermatology and gastroenterology. Its Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere, and Epkinly. The Company’s Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Its Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and Other eye care. Its Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its Venclexta is a B-cell lymphoma 2 (BCL-2) inhibitor used to treat blood cancers.
What is the stock price of ABBVIE INC today?
The current stock price of 4AB.DE is 201 EUR. The price decreased by -1.95% in the last trading session.
Does ABBVIE INC pay dividends?
ABBVIE INC (4AB.DE) has a dividend yield of 3.16%. The yearly dividend amount is currently 5.4.
What is the ChartMill rating of ABBVIE INC stock?
4AB.DE has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What do analysts say about ABBVIE INC (4AB.DE) stock?
37 analysts have analysed 4AB.DE and the average price target is 208.81 EUR. This implies a price increase of 3.88% is expected in the next year compared to the current price of 201.
Is ABBVIE INC (4AB.DE) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 4AB.DE.
What is the market capitalization of 4AB stock?
ABBVIE INC (4AB.DE) has a market capitalization of 355.08B EUR. This makes 4AB.DE a Mega Cap stock.
4AB.DE Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to 4AB.DE. When comparing the yearly performance of all stocks, 4AB.DE is one of the better performing stocks in the market, outperforming 87.23% of all stocks.
4AB.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to 4AB.DE. There are concerns on the financial health of 4AB.DE while its profitability can be described as average.
4AB.DE Financial Highlights
Over the last trailing twelve months 4AB.DE reported a non-GAAP Earnings per Share(EPS) of 8.13. The EPS decreased by -12.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 6.38% | ||
| ROA | 2.71% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
4AB.DE Forecast & Estimates
37 analysts have analysed 4AB.DE and the average price target is 208.81 EUR. This implies a price increase of 3.88% is expected in the next year compared to the current price of 201.
For the next year, analysts expect an EPS growth of 6.31% and a revenue growth 8.37% for 4AB.DE